Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chimerix, Inc. - Common Stock (NQ:CMRX)

8.530 +0.010 (+0.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Chimerix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
Via Benzinga
Dow Falls 150 Points; Oracle Posts Downbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
Chimerix plans to submit an NDA for dordaviprone to treat H3 K27M-mutant glioma, with potential U.S. FDA approval targeted for late 2025. 
Via Benzinga
Exposures Product Safety
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
From Chimerix, Inc.
Via GlobeNewswire
CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024
CMRX stock results show that Chimerix missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
From Chimerix, Inc.
Via GlobeNewswire
Preview: Chimerix's Earnings
Via Benzinga
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
CMRX Stock Earnings: Chimerix Meets EPS, Beats Revenue for Q2 2024
CMRX stock results show that Chimerix met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
From FN Media Group LLC
Via GlobeNewswire
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Appoints Marc D. Kozin to Board of Directors
Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience 
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
From Chimerix, Inc.
Via GlobeNewswire
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
From Chimerix, Inc.
Via GlobeNewswire
Chimerix Appoints Lisa Decker to Board of Directors
Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience 
From Chimerix, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.